Effect of ACU193, an Aβ Oligomer Targeting Monoclonal Antibody, on CSF & Plasma Biomarkers of Alzheimer’s Disease

Time: 4:00 pm
day: Conference Day One


  • Discussing ACU193’s reduction of ARIA in patients with ApoE4 variants without targeting plaque following the INTERCEPT-AD trial
  • Identifying CSF & plasma biomarkers and exploring the differences and approaches with this target
  • Using a bioanalytical target engagement approach to inform dosing and adaptive trial design for phase 2/3 studies